LENZ Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
5.5M
+188.6%
1.9M
+19.7%
1.6M
-87.3%
12.5M
+150.0%
5.0M
Cost of Revenue
280.0K
-74.0%
1.1M
+157.4%
418.0K
0
0
Gross Profit
5.2M
+531.0%
825.0K
-29.5%
1.2M
-90.6%
12.5M
+150.0%
5.0M
Operating Expenses
39.4M
-12.4%
45.0M
+13.4%
39.6M
+26.3%
31.4M
+43.6%
21.9M
R&D
0
0
0
-100.0%
3.8M
-58.2%
9.1M
SG&A
39.4M
-12.4%
45.0M
+13.4%
39.6M
+43.6%
27.6M
+115.7%
12.8M
Operating Income
-34172000
+22.6%
-44135000
-14.7%
-38463000
-103.6%
-18887000
-12.0%
-16857000
EBITDA
-34062000
+22.6%
-44024000
-14.8%
-38356000
-104.4%
-18762000
-11.4%
-16838000
Net Income
-31918000
+23.1%
-41488000
-15.6%
-35896000
-114.9%
-16700000
-12.0%
-14912000
EPS (Basic)
$-1.02
+22.7%
$-1.32
-14.8%
$-1.15
-94.9%
$-0.59
-11.3%
$-0.53
EPS (Diluted)
$-1.02
+22.7%
$-1.32
-14.8%
$-1.15
-94.9%
$-0.59
-11.3%
$-0.53
Shares (Diluted)
31.4M
+0.1%
31.4M
+0.8%
31.1M
+9.0%
28.5M
+1.6%
28.1M
LENZ Therapeutics (LENZ) โ€” Financials